Spago Nanomedical Tumorad-01 DMC says maximum tolerated dose met, adds two patients at 15 MBq/kg for RP2D definition

• Spago Nanomedical reported Tumorad-01 phase I/IIa data showed visible tumor uptake in another head and neck cancer patient.
• An independent monitoring committee concluded the study met its maximum tolerated dose endpoint, supporting a transition toward dose selection.
• Two more patients will be enrolled at a lower, split-dose regimen to set a recommended phase II dose and finish phase I.
• Trial results have already been presented at the ANZSNM meeting in May 2026, with further updates expected as phase I closes.
• Strategy shifted toward head and neck cancer, starting with adenoid cystic carcinoma, an orphan indication with no approved systemic treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spago Nanomedical AB published the original content used to generate this news brief on August 20, 2026, and is solely responsible for the information contained therein.